Legal & General Group Plc Has $8.23 Million Stock Holdings in Guardant Health, Inc. $GH

Legal & General Group Plc decreased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 7.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 158,069 shares of the company’s stock after selling 12,065 shares during the period. Legal & General Group Plc owned approximately 0.13% of Guardant Health worth $8,226,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in GH. Intech Investment Management LLC boosted its holdings in Guardant Health by 37.3% during the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company’s stock worth $2,564,000 after buying an additional 16,363 shares during the last quarter. Yorktown Management & Research Co Inc acquired a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $289,000. Osterweis Capital Management Inc. bought a new position in Guardant Health during the 1st quarter worth approximately $12,634,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Guardant Health by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,236 shares of the company’s stock valued at $3,035,000 after purchasing an additional 4,056 shares during the period. Finally, Strs Ohio bought a new stake in Guardant Health in the first quarter valued at approximately $809,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In related news, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the completion of the transaction, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,500 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $95.19, for a total transaction of $142,785.00. Following the sale, the director directly owned 815 shares in the company, valued at $77,579.85. This trade represents a 64.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 313,061 shares of company stock valued at $18,989,478 over the last 90 days. 6.10% of the stock is owned by corporate insiders.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $103.87 on Wednesday. The firm has a market cap of $13.09 billion, a price-to-earnings ratio of -32.36 and a beta of 1.58. The stock’s 50-day moving average is $81.90 and its 200-day moving average is $62.03. Guardant Health, Inc. has a one year low of $29.91 and a one year high of $112.43.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. During the same period last year, the business posted ($0.88) earnings per share. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GH. TD Cowen lifted their price target on shares of Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. BTIG Research lifted their target price on Guardant Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Morgan Stanley boosted their target price on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday. Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Thursday, October 30th. Finally, Piper Sandler boosted their price objective on Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.86.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.